BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.

The US Centers for Medicare & Medicaid Services (CMS) has finalized its national coverage determination (NCD) for transcatheter tricuspid valve replacement (TTVR) when used to treat patients with ...

CMS has approved Medicare and Medicaid coverage for transcatheter tricuspid valve replacement procedures for the treatment of symptomatic tricuspid regurgitation. The procedures will be subject to ...

The funding will be put towards an early feasibility study, designed to determine the clinical effectiveness and safety of Laplace’s transcatheter tricuspid valve replacement system. If successful, ...

US medical device company Laplace Interventional has completed a Series C financing round to support the completion of an early feasibility study (EFS) of its transcatheter tricuspid valve (TTV) ...

Valve has released the Steam year in review for 2024, in which the platform holder drowns us all in lovely stats and gives a snapshot of how we behave on the de facto PC gaming standard. Turns out ...

Tricuspid regurgitation (TR) is a known prognostic factor in heart diseases like heart failure and degenerative MR. It is also frequently observed in AFMR patients, making it crucial to understand ...

Lp(a) (lipoprotein(a)) is an independent risk factor for calcific aortic valve stenosis (CAVS). Whether patients with CAVS and high Lp(a) levels are at higher risk of valvular or cardiovascular events ...